Return to search

Inversago Pharma picks up $35m in Forbion-led Series B

Montreal-based Inversago Pharma, a peripheral CB1 blockade company, has raised US$35 million in Series B funding.

Montreal-based Inversago Pharma, a peripheral CB1 blockade company, has raised US$35 million in Series B funding. Forbion led the round with participation from other investors that included the Fonds de solidarité FTQ, Genesys Capital, JDRF T1D Fund, Amorchem, Anges Québec Capital and adMare BioInnovations.

Source: Press Release